Company news
Kodiak Sciences Inc (NASDAQ:KOD) news
Kodiak Sciences Inc news releases on 6ix. Latest, Sep 28, 2026: Zenkuda and tabirafusp-ted Meet Primary Endpoints in Pivotal DAYBREAK Trial in wAMD…
Press releases & updates
Zenkuda and tabirafusp-ted Meet Primary Endpoints in Pivotal DAYBREAK Trial in wAMD, with Zenkuda Demonstrating a Potential New Standard-of-Care Profile with Strong Immediacy and Sustained Clinical Effect with Majority of Patients on 24-week Dosing Interval Using Strict Treat-to-Dryness Real World Retreatment Criteria.
September 28, 2026
Kodiak Sciences to Present Topline Results on September 28, 2026 from DAYBREAK Pivotal Phase 3 Study of Zenkuda and KSI-501 in Patients with Wet Age-Related Macular Degeneration
September 25, 2026
Kodiak Sciences Announces Recent Business Highlights and Second Quarter 2026 Financial Results
August 13, 2026
Kodiak Sciences Announces First Patients Enrolled in Global Phase 3 ALTO trial of KSI-501 in Patients with Diabetic Macular Edema
August 10, 2026
Kodiak Sciences Completes Enrollment in First Pivotal Cohort in the Phase 3 PEAK Trial of KSI-101 for Macular Edema Secondary to Inflammation and Reaffirms Topline Clinical Data Release Remains on Track for December 2026
August 6, 2026
Kodiak Sciences to Present at 2026 Jefferies Global Healthcare Conference
May 28, 2026
Kodiak Sciences Announces Recent Business Highlights and First Quarter 2026 Financial Results
May 7, 2026
Kodiak Sciences to Present Pipeline Advances and KSI-101 Clinical Data, Including Results from a MESI Cohort in a Tertiary Care Uveitis Practice, at Upcoming Scientific Conferences
May 1, 2026
Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results
March 30, 2026
Kodiak Sciences Announces Positive Topline Results in GLOW2, the Second Phase 3 Study in Diabetic Retinopathy, Demonstrating Superiority of Zenkuda™ (tarcocimab tedromer) Over Sham
March 25, 2026
Final APEX Phase 1b Clinical Results for Kodiak's KSI-101 in Macular Edema Secondary to Inflammation to be Presented at Angiogenesis 2026
February 3, 2026
Kodiak Sciences to Present at 44th Annual J.P. Morgan Healthcare Conference
January 6, 2026
Kodiak Sciences Announces Closing of $184 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares
December 17, 2025
Kodiak Sciences Announces Pricing of Upsized Public Offering of Common Stock
December 15, 2025
Kodiak Sciences Announces Proposed Public Offering of Common Stock
December 14, 2025
Kodiak Sciences Announces Recent Business Highlights and Third Quarter 2025 Financial Results
November 12, 2025
Kodiak Sciences to Present at Upcoming Investor Conferences
November 11, 2025
Follow-up data for Kodiak's KSI-101 from the APEX study showed continued strengthening of clinical effect (≥90% of patients achieving absence of intraretinal and subretinal fluid) through week 20 in macular edema secondary to inflammation (MESI)
November 4, 2025
New data for Kodiak's KSI-101 from the APEX study reinforce its clinically meaningful vision gains and rapid retinal drying in macular edema secondary to inflammation (MESI)
September 14, 2025
Kodiak Sciences to Participate in Upcoming Scientific Conferences Highlighting KSI-101 in Patients with Macular Edema Secondary to Inflammation (MESI)
September 1, 2025
Kodiak Sciences to Present at American Chemical Society Fall 2025
August 18, 2025
Kodiak Sciences Announces Recent Business Highlights and Second Quarter 2025 Financial Results
August 12, 2025
Kodiak Sciences to Host Investor R&D Day on July 16, 2025
July 9, 2025
Kodiak Sciences to Present KSI-101 Highlights at 2025 Congress of the International Ocular Inflammation Society
June 24, 2025
Kodiak Sciences to Present at 2025 Jefferies Global Healthcare Conference
May 28, 2025
Kodiak Sciences Announces Recent Business Highlights and First Quarter 2025 Financial Results
May 13, 2025
Kodiak Sciences Data at ARVO 2025 Highlight Power and Versatility of ABC Platform in Addressing Complex Multifactorial Ocular Diseases
April 30, 2025
Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results
March 26, 2025
Kodiak Sciences Completes Enrollment in Second Registrational Trial of Tarcocimab in Patients with Diabetic Retinopathy
March 9, 2025
Kodiak Sciences to Present at Glaucoma 360 New Horizons Forum 2025
February 3, 2025
Kodiak Sciences to Present at 43rd Annual J.P. Morgan Healthcare Conference
January 6, 2025
Kodiak Sciences Announces Recent Business Highlights and Third Quarter 2024 Financial Results
November 13, 2024
Kodiak Sciences to Participate in Upcoming Investor Conferences
November 10, 2024
Kodiak Sciences to Present at Innovate Retina 2024
October 13, 2024
Kodiak Sciences to Host Investor R&D Day Today at 10:30am Eastern Time
September 22, 2024
Kodiak Sciences to Host Investor R&D Day on September 23, 2024 in New York City
September 16, 2024
Kodiak Sciences Announces Recent Business Highlights and Second Quarter 2024 Financial Results
August 13, 2024
Kodiak Sciences to Present at Upcoming Investor and Clinical Conferences
May 28, 2024
Kodiak Sciences Announces Recent Business Highlights and First Quarter 2024 Financial Results
May 14, 2024
Kodiak Sciences Announces Treatment of First Patients in Phase 3 GLOW2 Study of Tarcocimab Tedromer in Diabetic Retinopathy
May 12, 2024
Kodiak Sciences Data at ARVO 2024 Highlight Depth of Early and Late-Phase Retina Pipeline including Advancements with High Drug-Antibody-Ratio Therapeutics Built on Kodiak's Antibody Biopolymer Conjugate (ABC) Platform
May 1, 2024
Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
March 27, 2024
Kodiak Sciences to Report Fourth Quarter and Full-Year 2023 Financial Results and Host Business Updates Webcast on March 28, 2024
March 25, 2024
Kodiak Sciences Announces Upcoming Presentation of First Time Results of KSI-501ABC Phase 1 Study at the Angiogenesis, Exudation, and Degeneration 2024 Virtual Meeting
January 29, 2024
Kodiak Sciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 3, 2024
Kodiak Sciences to Present at the 6th Annual Evercore ISI HealthCONx Conference
November 20, 2023
Kodiak Sciences Announces Third Quarter 2023 Financial Results and Recent Business Highlights
November 13, 2023
Kodiak reboots tarcocimab tedromer development program following strong positive results in Phase 3 diabetic retinopathy GLOW study and following dialogue with US regulatory authorities on a regulatory pathway for BLA submission
November 5, 2023
KODIAK SCIENCES ANNOUNCES FIRST TIME PRESENTATION OF PRIMARY ENDPOINT DATA FROM TARCOCIMAB TEDROMER PHASE 3 GLOW STUDY IN PATIENTS WITH DIABETIC RETINOPATHY AT AMERICAN ACADEMY OF OPHTHALMOLOGY ANNUAL MEETING
October 31, 2023
Kodiak Sciences Announces Upcoming Presentations at the 56th Annual Scientific Meeting of the Retina Society
October 10, 2023